Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 9, 2020
Reporting Period: Single event date (April 9, 2020)
Business Context: The filing serves as a Regulation FD disclosure to distribute a presentation (Exhibit 99.1) and a summary (Exhibit 99.2) to the public. The registrant is an emerging growth company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to disseminate attached exhibits rather than a financial statement report.
Material Changes
No material changes to financial position or operations are detailed within the text of this Form 8-K. The filing references attached exhibits for substantive information.
Guidance, Outlook, and Risks
Management Commentary: The Company determined to use the attached presentation and summary for disclosure purposes.
Legal Status of Disclosure: The information in this Item 7.01 and the attached exhibits is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be incorporated by reference into other documents except as expressly set forth.
Risks and Contingencies: The filing text does not explicitly list risks or contingencies; these are likely contained within the referenced Exhibit 99.1 or 99.2.
Investor Verification Checklist
- Review Exhibit 99.1 (Presentation) and Exhibit 99.2 (Summary) attached to the filing for actual financial data and strategic updates.
- Verify the trading symbol (INMB) on the NASDAQ exchange.
- Confirm the Company's status as an emerging growth company and any associated accounting election implications.
- Note that the content of this specific 8-K text is not incorporated by reference into future registration statements unless explicitly stated.